Inventor · disambiguated record
Michael G. Johnson
Also filed as: JOHNSON MICHAEL · JOHNSON MICHAEL G · JOHNSON MICHAEL GARRETT
30 granted patents·12 pending applications·463 citations·filing 1993–2023
97Inventor score
Top patents by PatentIndex Score
42 records- 0198US6794379B2CXCR3 antagonistsTULARIK INC·Filed 2002·Granted Sep 21, 2004·101 cites·23 claims
- 0296US11299479B1Bisamide sarcomere activating compounds and uses thereofAMGEN INC·Filed 2020·Granted Apr 12, 2022·8 cites·23 claims
- 0396US10899746B2Bisamide sarcomere activating compounds and uses thereofAMGEN INC·Filed 2020·Granted Jan 26, 2021·5 cites·27 claims
- 0494US11780826B2Bisamide sarcomere activating compounds and uses thereofAMGEN INC·Filed 2022·Granted Oct 10, 2023·2 cites·19 claims
- 0594US5808139ANon-steroid progesterone receptor agonist and antagonist and compounds and methodsLIGAND PHARM INC·Filed 1994·Granted Sep 15, 1998·79 cites·27 claims
- 0693US10723720B2Bisamide sarcomere activating compounds and uses therofAMGEN INC·Filed 2018·Granted Jul 28, 2020·7 cites·21 claims
- 0792US10392376B2Heterocyclic inhibitors of ATR kinaseUNIV TEXAS·Filed 2018·Granted Aug 27, 2019·7 cites·32 claims
- 0892US7375102B2Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their useAMGEN SF LLC·Filed 2005·Granted May 20, 2008·27 cites·24 claims
- 0992US7053215B2Substituted Quinazolin-4(3H)-one compounds, compositions, and methods for their useAMGEN SF LLC·Filed 2002·Granted May 30, 2006·47 cites·18 claims
- 1091US7939538B2Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseasesAMGEN INC·Filed 2005·Granted May 10, 2011·20 cites·23 claims
- 1191US7067662B2CXCR3 antagonistsAMGEN SF LLC·Filed 2004·Granted Jun 27, 2006·31 cites·20 claims
- 1290US6964967B2Substituted pyrido[2,3-d]pyrimidines and methods for their useAMGEN INC·Filed 2001·Granted Nov 15, 2005·35 cites·28 claims
- 1390US5677336ANon-steroid androgen receptor antagonist compounds and methodsLIGAND PHARM INC·Filed 1993·Granted Oct 14, 1997·37 cites·4 claims
- 1489US10421765B2Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinaseUNIV TEXAS·Filed 2018·Granted Sep 24, 2019·7 cites·39 claims
- 1588US9593129B2Piperidinone derivatives as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2016·Granted Mar 14, 2017·5 cites·18 claims
- 1688US9296736B2Piperidinone derivatives as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2014·Granted Mar 29, 2016·7 cites·13 claims
- 1787US2024300892A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2023·Application pending·0 cites
- 1886US10800769B2Heterocyclic inhibitors of ATR kinaseUNIV TEXAS·Filed 2019·Granted Oct 13, 2020·2 cites·16 claims
- 1986US9376425B2Heterocyclic compounds as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2012·Granted Jun 28, 2016·12 cites·37 claims
- 2084US10745420B2Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinaseUNIV TEXAS·Filed 2019·Granted Aug 18, 2020·2 cites·26 claims
- 2183US2024158372A1Bisamide sarcomere activating compounds and uses thereofAMGEN INC·Filed 2023·Application pending·0 cites
- 2282US8940724B2Quinoline derivitives and their usesCUSHING TIMOTHY D·Filed 2010·Granted Jan 27, 2015·14 cites·8 claims
- 2381US11306107B2Compounds that inhibit MCL-1 proteinAMGEN INC·Filed 2017·Granted Apr 19, 2022·2 cites·11 claims
- 2480US2022169611A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2022·Application pending·0 cites
- 2577US7271271B2Imidazolo-related compounds, compositions and methods for their useAMGEN SF LLC·Filed 2005·Granted Sep 18, 2007·3 cites·14 claims
- 2676US10800774B2Heterocyclic inhibitors of ATR kinaseUNIV TEXAS·Filed 2018·Granted Oct 13, 2020·2 cites·25 claims
- 2774US10894052B2Heterocyclic inhibitors of ATR kinaseUNIV TEXAS·Filed 2019·Granted Jan 19, 2021·1 cites·32 claims
- 2874US2021179560A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2020·Application pending·0 cites
- 2969US12091425B2Compounds that inhibit MCL-1 proteinAMGEN INC·Filed 2021·Granted Sep 17, 2024·0 cites·7 claims
- 3067US11434233B2Heterocyclic inhibitors of ATR kinaseUNIV TEXAS·Filed 2020·Granted Sep 6, 2022·0 cites·21 claims
- 3167US2019062276A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2018·Application pending·0 cites
- 3265US2014011796A1Piperidinone derivatives as mdm2 inhibitors for the treatment of cancerAMGEN INC·Filed 2013·Application pending·0 cites
- 3364US2017144971A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2017·Application pending·0 cites
- 3463US2024262792A1Usp30 inhibitors and uses thereofVINCERE BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3557US2022332708A1Sulfonamide compounds as cardiac sarcomere activatorsCYTOKINETICS INC·Filed 2022·Application pending·0 cites
- 3655US8404722B2Oxazole compounds compositions and methods of useBROWN MATTHEW·Filed 2009·Granted Mar 26, 2013·0 cites·21 claims
- 3755US2006116388A1CXCR3 antagonistsAMGNEN SF LLC·Filed 2006·Application pending·0 cites
- 3851US11845724B2USP30 inhibitors and uses thereofVINCERE BIOSCIENCES INC·Filed 2020·Granted Dec 19, 2023·0 cites·21 claims
- 3950US7960567B2Compounds and methods useful for treating asthma and allergic inflammationAMGEN INC·Filed 2008·Granted Jun 14, 2011·0 cites·19 claims
- 4046US9873704B2Heterocyclic compounds and their usesAMGEN INC·Filed 2016·Granted Jan 23, 2018·0 cites·3 claims
- 4143US2010331306A1Heterocyclic compounds and their usesAMGEN INC·Filed 2010·Application pending·0 cites
- 4239US2004242498A1CXCR3 antagonistsFiled 2004·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michael G. Johnson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →